



FY25 Behavioral Health Grand Rounds

# Using Laboratory Science to Inform Clinical Decision Making and Patient Safety in Medicinal Cannabis

**Ryan Vandrey, PhD**  
Professor, Behavioral Pharmacology Research Unit  
Johns Hopkins University School of Medicine

**Virtual (Zoom)**  
<https://childrensnational.zoom.us/j/96102569437>

**Passcode: 3932**

**December 4, 2024**  
11 a.m. - 12 p.m.

To claim credit,  
text **JEZVAL**  
to 703.260.9391

**Dr. Vandrey** is an experimental psychologist and Professor at the Johns Hopkins University Behavioral Pharmacology Research Unit (BPRU) and helps lead the Cannabis Science Lab. Dr. Vandrey's research focuses primarily on the impact of route of administration, dose, and chemical composition of cannabis products on resultant drug effects and pharmacokinetics. In addition, Dr. Vandrey has been involved with a broad range of studies related to the risks and benefits of medicinal cannabis use, cannabis-drug interactions, the effects of cannabis use on sleep, cannabis withdrawal, the treatment of Cannabis Use Disorder, cannabis product testing, and developing measures of cannabis use behavior.

**Abstract:** Dr. Vandrey will give a talk that covers several areas of cannabis science. He will present data from human laboratory studies that characterize differences in the acute effects of cannabis use based on the chemical composition of the product, the route of administration, dose taken, and whether the drug was taken in combination with food or other drugs. He will also describe research projects he has been involved with that evaluated the health effects of medicinal cannabis use and concerns related to cannabis product safety. He will wrap up the talk by describing a new program he is helping lead called the Cannabis and Health Research Initiative (CHRI).

**Target audience:** Psychiatrists, Psychologists, Social Workers, Psychiatry fellows, Psychology Doctoral Interns

**Learning objectives:**

1. Describe the difference in time course of THC-related drug effects between cannabis products that are inhaled versus swallowed.
2. Be able to communicate potential risks associated with cannabis use to your patients
3. Identify medications for which metabolism could be altered by oral CBD products

**Accreditation:** The Medical Society of Virginia is a member of the Southern States CME Collaborative, an ACCME Recognized Accreditor. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Southern States CME Collaborative (SSCC) through the joint providership of Inova Health System Office of Continuing Medical Education and Children's National Hospital. Inova Health System Office of Continuing Medical Education is accredited by the SSCC to provide continuing medical education for physicians.

**Credit designation:** The Inova Office of Continuing Medical Education designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should only claim credit commensurate with the extent of their participation in the activity. Physicians may claim up to 1.0 credit in Type 1 CME on the Virginia Board of Medicine Continued Competency and Assessment Form required for renewal of an active medical license in Virginia.